Colleen Silk on Novo Nordisk Performance at ASH25
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”I’m so proud to have attended the 2025 ASH Annual Meeting in Orlando over the weekend alongside so many talented colleagues from our Hemoglobinopathies and Rare Blood Disorders teams.
It was so inspiring to see the dedication, expertise, and collaboration that went into making this meeting such a success for Novo Nordisk.
In addition to the great work that went into our exhibit booth and many poster and oral presentations, ASH was an invaluable opportunity to engage directly with the hematology community.
We had meaningful conversations with KOLs where we shared the science and our vision for expanding treatment options for people living with rare blood disorders and sickle cell disease.
These dialogues will help shape our path forward and accelerate the impact of our future portfolio.
A huge thank you to everyone who worked so hard to bring this to life.
From our US Field and Home Office cross-functional teams and our partners in Global, everyone contributed to making the congress truly outstanding.
I’m excited for what lies ahead for the Rare Disease team at Novo Nordisk as we continue to educate with the goal of bringing innovative therapies to patients who need them most.”

Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies